or Try an Advanced Search...

    Technical Analysis for GRI - GRI Bio, Inc.

    Grade Last Price % Change Price Change
    D 0.68 6.98% 0.04
    GRI closed down 6.76 percent on Wednesday, November 20, 2024, on 5 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical GRI trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 6.98%
    Wide Bands Range Expansion 6.98%
    Down 3 Days in a Row Weakness 6.98%
    Down 4 Days in a Row Weakness 6.98%
    Oversold Stochastic Weakness 6.98%
    NR7 Range Contraction -0.25%
    Narrow Range Bar Range Contraction -0.25%
    Stochastic Reached Oversold Weakness -0.25%
    Wide Bands Range Expansion -0.25%
    Down 3 Days in a Row Weakness -0.25%
    Older End-of-Day Signals for GRI ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 4 hours ago
    Up 3% about 4 hours ago
    Up 2% about 4 hours ago
    Up 1% about 4 hours ago
    Down 1% about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    GRI Chart by TradingView
    Basic chart:

    Profile

    GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Immunology Immune System Autoimmunity Liver Disease Natural Killer Cell Lymphocytes T Cell Natural Killer T Cell

    Is GRI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 2 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 GRI Bio reports 9M results
    Nov 14 GRI Bio files to sell 1.58M shares of common stock for holders
    Nov 14 GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
    Oct 24 GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
    Oct 21 GRI Bio Announces Exercise of Warrants
    Oct 16 GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
    Oct 7 GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
    Sep 30 GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
    Sep 26 GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
    Sep 25 GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
    See more GRI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 105.5691
    52 Week Low 0.3034
    Average Volume 5,285,692
    200-Day Moving Average 4.07
    50-Day Moving Average 0.63
    20-Day Moving Average 0.83
    10-Day Moving Average 0.81
    Average True Range 0.15
    RSI (14) 43.50
    ADX 34.21
    +DI 29.42
    -DI 20.21
    Chandelier Exit (Long, 3 ATRs) 0.89
    Chandelier Exit (Short, 3 ATRs) 1.04
    Upper Bollinger Bands 1.10
    Lower Bollinger Band 0.57
    Percent B (%b) 0.13
    BandWidth 63.18
    MACD Line 0.02
    MACD Signal Line 0.06
    MACD Histogram -0.0428
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.77
    Resistance 3 (R3) 0.78 0.74 0.75
    Resistance 2 (R2) 0.74 0.71 0.74 0.74
    Resistance 1 (R1) 0.69 0.69 0.67 0.68 0.73
    Pivot Point 0.66 0.66 0.65 0.65 0.66
    Support 1 (S1) 0.60 0.62 0.59 0.60 0.54
    Support 2 (S2) 0.57 0.60 0.56 0.54
    Support 3 (S3) 0.52 0.57 0.53
    Support 4 (S4) 0.51